Effect of gefitinib on warfarin antithrombotic activity-Reference-Cited by-同舟云学术

Effect of gefitinib on warfarin antithrombotic activity

Published:2009-08 Issue:4 Volume:14 Page:332-336
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Arai Susumu,Mitsufuji Hisashi,Nishii Yasuto,Onoda Sayaka,Ryuge Shinichiro,Wada Mayuko,Katono Ken,Iwasaki Maiko,Takakura Akira,Otani Sakiko,Yamamoto Michiko,Yanaihara Tomoko,Yokoba Masanori,Kubota Masaru,Katagiri Masato,Fukui Tomoya,Kobayashi Hirosuke,Yanase Nobuo,Hataishi Ryuji,Masuda Noriyuki

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

http://link.springer.com/content/pdf/10.1007/s10147-008-0871-2.pdf

Reference18 articles.

1. Brown MC (1999) An adverse interaction between warfarin and 5-fluorouracil: a case report and review of the literature. Chemotherapy 45:392–395

2. Cohen MH, Williams GA, Sridhara R, et al. (2004) United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 10:1212–1218

3. Cropp JS, Bussey HI (1997) A review of enzyme induction of warfarin metabolism with recommendations for patient management. Pharmacotherapy 17:917–928

4. Douillard J-Y, Kim ES, Hirsh V, et al. (2007) Phase III, randomized, open-label, parallel-group study of oral gefitinib (IRESSA) versus intravenous docetaxel in patients with locally advanced or metastatic non small cell lung cancer who have previously received platinum-based chemotherapy (INTEREST). Eur J Cancer 43(Suppl 5):2

5. Fukuoka M, Yano S, Giaccone G, et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21:2237–2246

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Erlotinib or Gefitinib for Treating Advanced Epidermal Growth Factor Receptor Mutation–Positive Lung Cancer in Aotearoa New Zealand: Protocol for a National Whole-of-Patient-Population Retrospective Cohort Study and Results of a Validation Substudy;JMIR Research Protocols;2024-07-02

2. Protein Kinase Inhibitors Indicated for Lung Cancer: Pharmacodynamics, Pharmacokinetics, Adverse Drug Reactions, and Evaluation in Clinical Trials;Journal of Clinical Pharmacy and Therapeutics;2024-01

3. Menahydroquinone-4 may play a key role in regulating CCL5 expression induced by epidermal growth factor receptor inhibitors;Scientific Reports;2023-12-13

4. Erlotinib or Gefitinib for Treating Advanced Epidermal Growth Factor Receptor Mutation–Positive Lung Cancer in Aotearoa New Zealand: Protocol for a National Whole-of-Patient-Population Retrospective Cohort Study and Results of a Validation Substudy (Preprint);2023-09-04

5. Medication guide for the perioperative management of oral antineoplastic agents in cancer patients;Expert Opinion on Drug Safety;2021-08-12